Amondys 45 + Vyondys 53 for Duchenne muscular dystrophy (label expansions)
One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Duchenne Muscular Dystrophy. Unsubscribe anytime.
The FDA is expected to decide on Amondys 45 + Vyondys 53 for Duchenne muscular dystrophy (label expansions) by February 28, 2027, under a sNDA from Sarepta Therapeutics.
What is being decided
Sarepta Therapeutics has a sNDA under FDA review for Amondys 45 + Vyondys 53 in Duchenne muscular dystrophy (label expansions). Label expansions for Sarepta's exon 45 and exon 53 skipping therapies.
Who this decision matters to
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginning in early childhood. The defective dystrophin protein normally protects muscle fibers from damage. Without it, muscles deteriorate and are gradually replaced by fat and scar tissue. Multiple exon-skipping therapies (eteplirsen, golodirsen, viltolarsen, casimersen) are FDA-approved. Delandistrogene moxeparvovec (Elevidys), the first gene therapy for DMD, received accelerated FDA approval in June 2023. In June 2024 the FDA granted traditional approval for ambulatory patients (those who can walk) aged 4 and older and accelerated approval for non-ambulatory patients. After 2 deaths from acute liver failure in non-ambulatory patients, the FDA announced an investigation in June 2025, and in July 2025 it asked Sarepta to pause all shipments; on July 28, 2025 it recommended that treatment of ambulatory patients resume. In November 2025, the FDA added a boxed warning (its most serious warning) for acute serious liver injury and acute liver failure, including deaths, and limited the indication to ambulatory patients aged 4 and older, so Elevidys is no longer approved for non-ambulatory patients.
Prevalence: 1 in 3,500 to 5,000 male births. See our full Duchenne Muscular Dystrophy page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Duchenne Muscular Dystrophy treatment stands today
Read our full Duchenne Muscular Dystrophy treatment summary
DMD research is remarkably active, with multiple exon-skipping therapies approved or in advanced trials, offering hope for slowing or stabilizing disease progression. Two newer oral medicines are FDA approved for DMD regardless of the specific mutation: vamorolone (Agamree), a once-daily corticosteroid liquid approved in October 2023 for patients 2 years and older, and givinostat (Duvyzat), a twice-daily histone deacetylase (HDAC) inhibitor liquid that targets inflammation and muscle loss, approved in March 2024 for patients 6 years and older.
Gene therapy approaches are expanding, and newer antisense oligonucleotides are being tested for additional dystrophin mutations. The Muscular Dystrophy Association maintains a comprehensive trial database.
These advances are most impactful when started early, so if you have a recently diagnosed child, discuss with your neurologist which newer therapies might be appropriate and monitor emerging trial opportunities. Genetic testing to identify your specific dystrophin mutation can help determine which targeted therapies you're eligible for.
The Duchenne Muscular Dystrophy page has every treatment and trial →Meanwhile, 75 Duchenne Muscular Dystrophy trials are recruiting
Whatever the FDA decides here, research on Duchenne Muscular Dystrophy does not stop. A few currently enrolling studies, US sites first:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Duchenne Muscular Dystrophy. Unsubscribe anytime.
Our coverage
Frequently asked questions
When will the FDA decide on Amondys 45 + Vyondys 53?
The FDA's target date (PDUFA date) for Amondys 45 + Vyondys 53 in Duchenne muscular dystrophy (label expansions) is February 28, 2027.
Who disclosed it: Sarepta Therapeutics. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Sarepta press release
What is Amondys 45 + Vyondys 53 being reviewed for?
Sarepta Therapeutics submitted a sNDA for Amondys 45 + Vyondys 53 in Duchenne muscular dystrophy (label expansions).
What to know: Label expansions for Sarepta's exon 45 and exon 53 skipping therapies.
Is there already an FDA-approved treatment for Duchenne Muscular Dystrophy?
Yes. Trial Friend's drug list includes 8 FDA-approved drugs for Duchenne Muscular Dystrophy.
Approved: Exondys 51 (eteplirsen), Emflaza (deflazacort), Vyondys 53 (golodirsen), Viltepso (viltolarsen), Amondys 45 (casimersen), Elevidys (delandistrogene moxeparvovec), Agamree (vamorolone), Duvyzat (givinostat).
Check: the Duchenne Muscular Dystrophy page also searches FDA drug labels for approved treatments.
Can I get Amondys 45 + Vyondys 53 before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 75 Duchenne Muscular Dystrophy trials are recruiting now. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Sarepta Therapeutics directly. Registered programs are listed on ClinicalTrials.gov.
How much will Amondys 45 + Vyondys 53 cost?
Sarepta Therapeutics has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Amondys 45 + Vyondys 53 decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Sarepta press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.